

سامية محمد مصطفى



شبكة المعلومات الجامعية

بسم الله الرحمن الرحيم



سامية محمد مصطفى



شبكة المعلومات الجامعية



شبكة المعلومات الجامعية التوثيق الالكتروني والميكروفيلم



سامية محمد مصطفى



شبكة المعلومات الجامعية

جامعة عين شمس

التوثيق الإلكتروني والميكروفيلم

قسم

نقسم بالله العظيم أن المادة التي تم توثيقها وتسجيلها
علي هذه الأقراص المدمجة قد أعدت دون أية تغيرات



يجب أن

تحفظ هذه الأقراص المدمجة بعيدا عن الغبار



سامية محمد مصطفى



شبكة المعلومات الجامعية



بعض الوثائق الأصلية تالفة



سامية محمد مصطفى



شبكة المعلومات الجامعية



بالرسالة صفحات لم ترد بالأصل



**Comparative Study on the Efficacy of Diphenylcyclopropenone
Alone and in Combination with Intralesional or Systemic
Corticosteroids for the Treatment of Extensive
or Refractory Alopecia Areata**

A Thesis

Submitted for partial fulfillment of Master degree
in **Dermatology and Venereology**

By

Noor Nofel Mohammed

M.B.B.,Ch.

Mosul University

Under Supervision of

Dr. Ahmad Ibrahim El-Sayed Rasheed

Professor of Dermatology and Venereology
Faculty of Medicine – Ain Shams University

Dr. Marwa Yassin Soltan

Lecturer of Dermatology and Venereology
Faculty of Medicine – Ain Shams University

**Faculty of Medicine
Ain Shams University
2019**



وَأَنْزَلَ اللَّهُ عَلَيْكَ
الْكِتَابَ وَالْحِكْمَةَ
وَعَلَّمَكَ مَا لَمْ تَكُنْ
تَعْلَمُ وَكَانَ فَضْلُ
اللَّهِ عَلَيْكَ عَظِيمًا

صدق الله العظيم

سورة النساء الآية (١١٣)



Acknowledgments

*First and foremost, I feel always indebted to **Allah**, the Most Beneficent and Merciful.*

*I wish to express my deepest gratitude and thanks to **Dr. Ahmad Ibrahim El-Sayed Rasheed**, Professor of Dermatology and Venereology, Faculty of Medicine – Ain Shams University, for his constructive criticism, unlimited help and giving me the privilege to work under his supervision. May Allah keep him sunlight of knowledge for his students.*

*My most sincere gratitude is also extended to **Dr. Marwa Yassin Soltan**, Lecturer of Dermatology and Venereology, Faculty of Medicine – Ain Shams University, for her enthusiastic help, continuous supervision, guidance and support throughout this work.*

*Last but not least, I can't forget to thank all members of my Family, especially my **Husband** and my **Parents**, for pushing me forward in every step in the journey of my life.*

Candidate

 **Noor Nofel Mohammed**



List of Contents

<i>Subject</i>	<i>Page No.</i>
List of Abbreviations	i
List of Tables.....	ii
List of Figures	iv
1. Introduction	1
2. Aim of the Work.....	4
3. Review of Literature.....	5
3.1. Overview of Alopecia Areata	5
3.2. Treatment options in Alopecia areata.....	27
4. Patients and Methods.....	43
5. Results.....	55
6. Discussion	89
7. Conclusions and recommendations	95
8. Summary	97
References	101
Arabic Summary	—

List of Abbreviations

<i>Abbr.</i>	<i>Full-term</i>
AA	: Alopecia areata
APCs	: Antigen-presenting cells
AT	: Alopecia totalis
AU	: Alopecia universalis
CMV	: Cytomegalovirus
DPCP	: Diphenylecyclopropenone
IHME	: Institute for Health Metrics and Evaluation
IL	: Interleukin
ILCs	: Intralesional corticosteroids
INF-γ	: Interferon-gamma
IP	: Immune privilege
JAK	: Janus kinase
PRP	: Platelet-rich plasma
PUVA	: Psoralen plus ultraviolet A
SADBE	: Squaric acid dibutylester
SD	: Standard deviation
SPSS	: Statistical package for social science
TGF	: Transforming growth factor
TR1	: Type 1 regulatory T cell
YD	: Yellow dots

List of Tables

<i>Table No.</i>	<i>Title</i>	<i>Page No.</i>
Table (1):	Poor prognostic factors for AA	26
Table (2):	The dilution for diphenylcyclopropenone	48
Table (3):	The personal and clinical characteristics of AA among the patients enrolled in the study	57
Table (4):	Demographic and clinical characteristics among AA patients in the three treatment groups	58
Table (5):	Clinical characteristics of the current incident of AA among the study cases	60
Table (6):	Dermoscopic findings in AA patients included in the study.....	61
Table (7):	Efficacy of treatment modalities among AA cases.....	64
Table (8):	Comparison between three groups as regards efficacy of treatment modalities among AA cases.....	65
Table (9):	Relapse, resistance and patient satisfaction among the study group	76
Table (10):	Safety and tolerability of treatment modalities	77
Table (11):	Pattern of common side effects among the study groups	78
Table (12):	Relation of treatment efficacy as percent of hair regrowth with family history of AA	84

Table (13): Relation of treatment efficacy as percent of hair regrowth with past history of similar condition.....	85
Table (14): Relation of treatment efficacy as percent of hair regrowth with affected site.....	86
Table (15): Relation of treatment efficacy as percent of hair regrowth with duration of current illness.....	87

List of Figures

<i>Figure No.</i>	<i>Title</i>	<i>Page No.</i>
Figure (1):	The normal hair cycle.	8
Figure (2):	Summary of events involved in disease pathogenesis of AA.....	11
Figure (3):	Possible pathogenetic events in AA. Genes up-regulated in AA are shown in red and those down-regulated are shown in blue.....	13
Figure (4):	Visual aid (Olsen/Canfield) for estimating percentage scalp hair loss.....	20
Figure (5):	Histopathological findings in AA.	22
Figure (6):	The treatment plan for AA classified according age of the patient.....	42
Figure (7):	The response of the skin to the sensitization by the DCPC.	49
Figure (8):	Visual aid (Olsen/Canfield) for estimating percentage scalp hair loss.....	51
Figure (9):	The dermoscopic findings of AA cases	62
Figure (10):	A 17 year old male patient with refractory AA who received treatment of DPCP and intralesional corticosteroid.....	66
Figure (11):	A 19 year old male patient with refractory AA who received treatment of DPCP alone.....	67

- Figure (12):** A 22 year old male patient with extensive AA from group II who received treatment of DPCP and intralesional corticosteroid. 68
- Figure (13):** A 42 year old male patient with AA totalis from group III who received treatment of DPCP and intramuscular corticosteroid..... 69
- Figure (14):** A 16 year old male patient with AA totalis from group III who received treatment of DPCP and intramuscular corticosteroid..... 70
- Figure (15):** A 26 year old male patient with refractory AA from group III who received treatment of DPCP and intramuscular corticosteroid. ... 71
- Figure (16):** A 40 year old male patient with refractory AA from group I who received treatment of DPCP alone..... 72
- Figure (17):** A 16 year old male patient with refractory AA from group II who received treatment of DPCP and intralesional corticosteroid. 73
- Figure (18):** A 15 year old female patient with extensive AA from group II who received treatment of DPCP and intralesional corticosteroid..... 74
- Figure (19):** Development of vitiligo as side effect at site of DPCP application at week 12. 79
- Figure (20):** Vitiligo development on the remote site of DPCP application at week 12 80
- Figure (21):** Vitiligo development on the scalp at the site of DPCP application at week 12. 81

- Figure (22):** Extensive reaction, eczematization with development of erythema and vesiculation developed after 48 hours of DPCP application, A and B: clinical picture 82
- Figure (23):** Relation of the treatment efficacy of treatment measured by the hair regrowth rate and the age of first onset (Linear regression, p value = 0.023)..... 88